Cardiovascular disease in HIV infection

Current Opinion in HIV and AIDS

Volumn 6, Issue 4, 2011, Pages 266-271

  Palella Jr , Frank J ^a   Phair, John P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cardiovascular disease in HIV infection; effects of antiretroviral drugs; hypercoagulation; hyperlipidemia; inflammation; vascular functioning

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; INDINAVIR; LOPINAVIR; LOW DENSITY LIPOPROTEIN; RITONAVIR;

ARTERIAL WALL THICKNESS; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DISEASE COURSE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; LIPODYSTROPHY; MORTALITY; MULTIVARIATE ANALYSIS; OBESITY; PRIORITY JOURNAL; REVIEW; SMOKING; SUBCUTANEOUS FAT; SURVIVAL;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 79959359930     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328347876c     Document Type: Review

References (65)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
2. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
3. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
4. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145:397-406. (Pubitemid 46768570)
5. Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
6. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
7. Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993; 76:1423-1427. (Pubitemid 23164355)
8. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008; 199:79-86. (Pubitemid 351842701)
9. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. J Am Med Assoc 2003; 289:2978-2982. (Pubitemid 37430100)
10. Tracy RP. Epidemiological evidence for inflammation in cardiovascular disease. Thromb Haemost 1999; 82:826-831.
11. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565. (Pubitemid 35315836)
12. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5:e78.
13. Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70. (Pubitemid 43063843)
14. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435-447.
15. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22:1615-1624.
16. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275-2283. (Pubitemid 44789529)
17. Schillaci G, De Socio GV, Pucci G, et al. Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertension 2008; 52:308-313.
18. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
19. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13:177-187. Study of increased risk for cardiovascular events associated with interruption of ARV.
20. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
21. Karpatkin S, Nardi M, Green D. Platelet and coagulation defects associated with HIV-1-infection. Thromb Haemost 2002; 88:389-401. (Pubitemid 35021595)
22. Bussolino F, Mitola S, Serini G, et al. Interactions between endothelial cells and HIV-1. Int J Biochem Cell Biol 2001; 33:371-390. (Pubitemid 32324005)
23. de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004; 4:213-222.
24. Baliga RS, Chaves AA, Jing L, et al. AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. Am J Physiol Heart Circ Physiol 2005; 289:H1373-H1380. (Pubitemid 41368977)
25. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42:1325-1332.
26. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185:456-462. (Pubitemid 34142807)
27. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569-576. Describes impact in untreated HIV infection on vascular endothelial function and the subsequent changes observed with HIV-suppressive HAART.
28. Grunfeld Carl D, Wanke C, Currier J, et al., and FRAM Study. HIV infection is an independent risk factor for atherosclerosis similar in magnitude to traditional cardiovascular disease risk factors. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2011.
29. Kingsley LA, Cuervo-Rojas J, Munoz A, et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS 2008; 22:1589-1599. Comparisons of coronary calcium levels among HIV-infected and uninfected men in the Multicenter AIDS Cohort Study (MACS).
30. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
31. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099. (Pubitemid 29278477)
32. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62. Review of HIV-associated anthropometric abnormalities and their associations with CVD risk.
33. Guaraldi GZS, Orlando G, Federica C, et al. Visceral fat but not general adiposity is a predictor of cardiovascular disease in HIV-infected males. 17th Conference on Retroviruses and Opportunistic Infections. [Abstract no. 703] (in press).
34. Dube MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis 2008; 47:567-574.
35. Lee GA, Lo JC, Aweeka F, et al. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006; 43:658-660. (Pubitemid 44267131)
36. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262. (Pubitemid 32666944)
37. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007; 44:493-499. (Pubitemid 46594891)
38. Shankar SS, Dube MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005; 150:933.
39. Kamin D, Hadigan C, Lehrke M, et al. Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J Clin Endocrinol Metab 2005; 90:3423-3426. (Pubitemid 41014307)
40. Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord 2005; 5:255-262. (Pubitemid 41448371)
41. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193. (Pubitemid 36667761)
42. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-710. (Pubitemid 36237039)
43. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328. (Pubitemid 28195913)
44. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748. (Pubitemid 35447907)
45. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471-477.
46. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486. (Pubitemid 38393320)
47. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735. (Pubitemid 46658704)
48. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
49. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001; 15:329-334. (Pubitemid 32163818)
50. Sabin CA, d'Arminio Monforte A, Friis-Moller N, et al. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008; 46:1101-1110. Description of longitudinal changes in rates of classic CVD risks, increases in the use of lipid-lowering therapies, and MI rates from the D:A:D study.
51. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426. Original study that suggests an association between abacavir use and increased risk for myocardial infarctions.
52. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144. (Pubitemid 351590049)
53. Lang SM-KM, Cotte L, Gilquin J, et al., and the Clinical Epi Group of the French Hosp Database on HIV Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction: a case-control study nested within FHDH ANRS CO4. 16th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2009.
54. Benson C, Ribaudo H, Zheng E, et al., and the ACTG A5001/ALLRT Protocol Team. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. 16th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2009.
55. Bedimo R, Westfall A, Drechsler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, South Africa, January, 2009.
56. Durand MSO, Baril J-G, Lelorier J, Tremblay C. Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID). 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, South Africa, January, 2009.
57. Ding XA-CE, Cooper C, Miele P, et al. No Association of myocardial infarction with ABC use: an FDA meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February. Boston, MA, 2009.
58. Palella FJ Jr, Gange SJ, Benning L, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24:1657-1665.
59. McComsey G, Smith K, Patel P, et al. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine: The HEAT Study. 16th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2009.
60. Hsue PWY, Schnell A, Ganz P, et al. Association of abacavir and HIV disease factors with endothelial function in patients on long-term suppressive ART. 16th Conference on Retroviruses and Opportunistic Infections, 2009 [Abstract no. 723] (in press).
61. Baum P, Kosikova G, Galkina S, et al. Abacavir, a competitive inhibitor of soluble guanylyl cyclase, increases platelet reactivity. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February, 2010.
62. Mehta SH, Moore RD, Thomas DL, et al. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003; 33:577-584. (Pubitemid 36975845)
63. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-705. (Pubitemid 29383638)
64. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 2000; 25 (Suppl 1):S4-S11.
65. Worm S, Kamara A, El-Sadr W, et al., and on behalf of the D:A:D Study Group. Triglycerides and the risk of myocardial infarction in the D:A:D study. 17th Conference on Retroviruses and Opportunistic Infections, February, San Francisco, CA, 2010.